ROR1 and B-cell chronic lymphocytic leukemia: Preclinical studies have confirmed the selective cytotoxicity of this ADC against ROR1-positive CLL cells, which allowed clinical trials to begin with this ADC, known as zilovertamab vedotin (MK-2140, VLS).